HCPCS Level II code A9587 identifies Gallium Ga-68 DOTATATE in a 0.1 millicurie unit for diagnostic molecular imaging. This radiopharmaceutical is used in PET imaging to detect somatostatin receptor–positive neuroendocrine tumors and other indications where somatostatin receptor targeting is clinically relevant. Nationally, accurate coding for radiopharmaceuticals is important for appropriate reimbursement, supply-chain tracking, and ensuring consistent access to specialized diagnostic tools.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and typical sites of service, an outline of common billing modifiers and their relevance, and notes on where data were available or not. The publication covers billing and coding benchmarks, payer coverage tendencies, and practical considerations for documenting radiopharmaceutical diagnostic services. It also highlights where input data were not provided and directs readers to seek payer-specific policy language for coverage criteria and prior authorization requirements.

This summary is written for a national audience and focuses on the purpose of the code, payer landscape, and the operational implications of using HCPCS Level II code A9587 for diagnostic Gallium Ga-68 DOTATATE.